PPL-138
Acute & Chronic Pain, Opioid Addiction, PTSD
Pre-clinicalActive
Key Facts
Indication
Acute & Chronic Pain, Opioid Addiction, PTSD
Phase
Pre-clinical
Status
Active
Company
About Phoenix PharmaLabs
Phoenix PharmaLabs is a U.S.-based drug developer targeting the opioid crisis with a pipeline of next-generation, non-addictive pain medications. Its lead asset, PPL-138, demonstrates high potency without the euphoric 'high' of mu-opioid receptor agonists, based on robust preclinical data. The company is funded primarily by U.S. government grants and private investment, with plans to advance into Phase 1 clinical trials. Phoenix seeks partnerships to co-develop and commercialize its candidates for significant unmet needs in pain management and addiction treatment.
View full company profile